Nordic NanoVector nordicnanovector.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers. The Company's lead clinical-stage product opportunity is Betalutin, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs) designed to improve upon and complement current options for the treatment of Non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.

Nordic Nanovector is focusing on the development and commercialization of novel targeted therapeutics for haematological cancers. The Company's lead clinical-stage product opportunity is Betalutin, the first in a new class of Antibody-Radionuclide-Co...Show all

Company (IPO / Went public)

Phone: +47 22 18 33 01

Fax:

Kjelsåsveien 168 B

Oslo, NO-0884
Norway

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Nordic NanoVector $8.3M Jul 7, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Nordic NanoVector Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Radioimunoconjugates and uses thereof Dec 09, 2013 Jun 07, 2016 Patent
Radioimmunoconjugates and uses thereof Jan 28, 2011 Jan 14, 2014 Patent
Method for upregulating antigen expression Jun 06, 2014 Application
Chimeric therapeutic anti - cd37 antibodie hh1 Dec 12, 2012 Application